尿液蛋白质组分析用于慢性肾脏病的无创诊断
研究利用1180例尿液样本的毛细管电泳-质谱蛋白质组数据,其中706例为发现队列、474例为独立验证队列,针对7种慢性肾脏病(CKD)类型构建支持向量机分类器,验证显示区分各CKD类型的曲线下面积为0.77至0.95,提示尿液蛋白质组分析有潜力识别经肾活检病理评估和当前临床实践定义的各类CKD。
要点
- 基于尿液蛋白质组数据构建的SVM分类器可区分7种CKD类型,验证队列AUC为0.77至0.95。
- 每种CKD类型的候选尿液生物标志物肽段数量为116至619个。
- 生物标志物序列分析可提供可能阐明潜在病理生理的信息。
核心结论
- 尿液蛋白质组分析有潜力识别经肾活检病理评估和当前临床实践定义的各类CKD。
- 这些方法可能为按CKD类型建模分子变化提供信息。
研究设计与样本
- 研究使用1180例不同类型CKD患者尿液样本的蛋白质组分析数据,由毛细管电泳耦合质谱产生。
- 706例样本作为发现队列,474例样本用于独立验证。
主要发现
- 针对7种不同CKD类型,定义了若干候选尿液生物标志物肽段(范围为116至619个肽段),并组合成每种CKD特异的SVM分类器。
- 这些分类器在独立队列中验证,区分一种CKD类型与其他类型显示出良好至优秀的准确度(受试者工作特征曲线下面积范围为0.77至0.95)。
- 生物标志物的序列分析提供了可能阐明潜在病理生理的进一步信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In spite of its invasive nature and risks, kidney biopsy is currently required for precise diagnosis of many chronic kidney diseases (CKDs). Here, we explored the hypothesis that analysis of the urinary proteome can discriminate different types of CKD irrespective of the underlying mechanism of disease. METHODS: We used data from the proteome analyses of 1180 urine samples from patients with different types of CKD, generated by capillary electrophoresis coupled to mass spectrometry. A set of 706 samples served as the discovery cohort, and 474 samples were used for independent validation. For each CKD type, peptide biomarkers were defined using statistical analysis adjusted for multiple testing. Potential biomarkers of statistical significance were combined in support vector machine (SVM)-based classifiers. RESULTS: For seven different types of CKD, several potential urinary biomarker peptides (ranging from 116 to 619 peptides) were defined and combined into SVM-based classifiers specific for each CKD. These classifiers were validated in an independent cohort and showed good to excellent accuracy for discrimination of one CKD type from the others (area under the receiver operating characteristic curve ranged from 0.77 to 0.95). Sequence analysis of the biomarkers provided further information that may clarify the underlying pathophysiology. CONCLUSIONS: Our data indicate that urinary proteome analysis has the potential to identify various types of CKD defined by pathological assessment of renal biopsies and current clinical practice in general. Moreover, these approaches may provide information to model molecular changes per CKD.
引用
- Siwy J, Zürbig P, Argiles A, et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant. 2017. PMID: 27984204. doi:10.1093/ndt/gfw337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。